4SC AG / Contract 04.06.2008 Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Planegg-Martinsried, Germany, 04 June 2008 Martinsried-based drug discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC) today announced the signing of a contract to acquire several projects from the oncology portfolio of Nycomed. The total purchase price amounts to 14 million euros. In this transaction, 4SC AG acquires all rights to eight of Nycomeds oncology projects, including one project in clinical phase I. This marks a significant expansion of the companys clinical and pre-clinical portfolio. The transaction is due to be completed by 31 July 2008. In return, Nycomed will receive a cash payment from 4SC AG totalling 14 million euros. The financing for this transaction and for the further development of the projects by 4SC AG is to be provided by raising additional funding, which amounts to 25 million euros. This financing is supported by Santo Holding (Deutschland) GmbH, the largest single shareholder in 4SC AG. No final decision has yet been made about the exact form it will take (equity capital or by drawing on a corporate loan already agreed upon). --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: About 4SC: 4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now with a staff of 74, the company develops novel drug candidates for inflammatory diseases, cancer and infectious diseases using a cheminformatics based technology platform. Traditional high throughput screening of therapeutic agents has been transferred from the lab to the computer. Thus, the company offers substantial cost and time advantages as well as increased success rates in drug development. 4SC AG utilises its technology platform, which is protected by patent, to create a sustainable project pipeline of active agents to be developed up to the early clinical phases ('proof of concept') and subsequently licensed to the pharmaceutical industry in return for advance and milestone payments as well as royalties. There are currently six projects in the pipeline and a so-called ideas pool with further development candidates. The first project for the treatment of rheumatoid arthritis has already successfully completed clinical phase IIa. Four other product candidates are in pre-clinical development and another project is in the research stage. In addition, the company is implementing its technology platform in partnerships with pharmaceutical and biotechnology companies, and is already generating initial revenues. Legal Note This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors. Bettina von Klitzing Manager Investor Relations & Public Relations 4SC AG Tel.: +49 (0) 89 70 07 63 - 0 Bettina.von.klitzing@4sc.com DGAP 04.06.2008 --------------------------------------------------------------------------- Language: English Issuer: 4SC AG Am Klopferspitz 19a 82152 Martinsried Deutschland Phone: +49 (0)89 7007 63-0 Fax: +49 (0)89 7007 63-29 E-mail: public@4sc.com Internet: www.4sc.de ISIN: DE0005753818 WKN: 575381 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: 4SC to acquire Nycomed oncology projects
| Source: EQS Group AG